Hirudinaria bpling Anticoagulant Family
Chromosome-level genome of H. bpling (Khan 2025) annotates 20+ anticoagulant gene families including 'Bplins' — a novel species-specific factor family.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Chromosome-level genome of H. bpling (Khan 2025) annotates 20+ anticoagulant gene families including 'Bplins' — a novel species-specific factor family.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
The H. bpling anticoagulant gene-family annotation is at the genome / phylogenetic level only. Functional in vitro / in vivo characterization of the 'Bplins' family or other H. bpling-specific factor variants is pending. No FDA-approved derivative exists; H. bpling is not the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Source species
- Hirudinaria bpling
- Discovered
- 2025 · Khan MS et al.
Biological Targets
- → coagulation cascade (predicted, multi-target across 20+ annotated anticoagulant gene families)
Key Citations
- Khan MS et al. (2025), BMC Genomics · PMID 40461966
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.